Physician profile
Sarah E Smith
NPI 1477871689
$19,673.60
in general payments reported to CMS, 2019-2025
24 companies · $14.65 in 2025
The $14.65 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $13K · 2021: $5,978 · 2022: $158 · 2023: $21.96 · 2024: $158 · 2025: $14.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18,681.84 | 2019-2022 | |
| Abbott Laboratories | $197.59 | 2019-2024 | Cardiomems |
| Novo Nordisk INC | $132.86 | 2019-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $108.45 | 2019-2021 | |
| Amgen INC. | $83.66 | 2019-2022 | |
| Ibsa Pharma INC. | $43.67 | 2021-2024 | Tirosint, Licart |
| Janssen Biotech, INC. | $39.72 | 2022-2023 | Tremfya |
| Corcept Therapeutics | $37.54 | 2019-2020 | |
| Horizon Therapeutics Plc | $34.33 | 2020-2021 | |
| Insulet Corporation | $33.19 | 2019-2020 | |
| Shire North American Group INC | $33.19 | 2019 | |
| Amarin Pharma, INC. | $29.37 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.50 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.58 | 2022 | |
| Aurinia Pharma U.S., INC. | $21.74 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.67 | 2019 | |
| Abbvie INC. | $18.50 | 2020 | |
| Medtronic Minimed, INC. | $17.79 | 2019 | |
| Pfizer INC. | $16.55 | 2022 | |
| Emd Serono, INC. | $16.32 | 2020 | |
| Merck Sharp & Dohme LLC | $15.42 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.09 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.65 | 2019 | |
| Companion Medical, INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.